Page 65 - JCTR-9-4

Li et al. | Journal of Clinical and Translational Research 2023; 9(4): 272-281 281
[19] Sun X, Liu L, Wan T, Huang Q, Chen J, Luo R, et al. The [30] Hoskins PJ, Swenerton KD, Pike JA, Lim P,
Prognostic Impact of the Immune Microenvironment in Aquino-Parsons C, Wong F, et al. Small-cell Carcinoma
Small-cell Neuroendocrine Carcinoma of the Uterine of the Cervix: Fourteen Years of Experience at a Single
Cervix: PD-l1 and Immune Cell Subtypes. Cancer Cell Int Institution Using a Combined-modality Regimen of
2022;22:348. Involved-field Irradiation and Platinum-based Combination
[20] Carroll MR, Ramalingam P, Salvo G, Fujimoto, Soto LMS, Chemotherapy. J Clin Oncol 2003;21:3495-501.
Phoolcharoen N, et al. Evaluation of PARP and PDL-1 as [31] Bajaj A, Gopalakrishnan M, Harkenrider MM, Lurain JR,
potential therapeutic targets for women with high-grade Small W Jr. Advanced Small Cell Carcinoma of the Cervix-
neuroendocrine carcinomas of the cervix. Int J Gynecol successful Treatment with Concurrent Etoposide and
Cance 2020;30:1303-7. Cisplatin Chemotherapy and Extended Field Radiation:
[21] Cimic A, Vranic S, Arguello D, Contreras E, Gatalica Z, A Case Report and Discussion. Gynecol Oncol Rep
Swensen J. Molecular Profiling Reveals Limited Targetable 2018;23:4-6.
Biomarkers in Neuroendocrine Carcinoma of the Cervix. [32] Cohen JG, Kapp DS, Shin JY, Urban R, Sherman AE,
Appl Immunohistochem Mol Morphol 2021;29:299-304. Chen LM, et al. Small Cell Carcinoma of the Cervix:
[22] Gu X, Dong M, Liu Z, Mi Y, Yang J, Zhang Z, et al. Treatment and Survival Outcomes of 188 Patients. Am J
Elevated PD-L1 Expression Predicts Poor Survival Obstet Gynecol 2010;203:347.e1-6.
Outcomes in Patients with Cervical Cancer. Cancer Cell [33] Chen CC, Wang L, Lin JC, Jan JS. The Prognostic Factors
Int 2019;19:146. for Locally Advanced Cervical Cancer Patients Treated by
[23] Enwere EK, Kornaga EN, Dean M, Koulis TA, Phan T, Intensity-modulated Radiation Therapy with Concurrent
Kalantarian M, et al. Expression of PD-L1 and Presence of Chemotherapy. J Formos Med Assoc 2015;114:231-7.
CD8-positive T Cells in Pre-treatment Specimens of Locally [34] Yamashita H, Nakagawa K, Tago M, Shiraishi K,
Advanced Cervical Cancer. Mod Pathol 2017;30:577-86. Nakamura N, Ohtomo K. Treatment Results and Prognostic
[24] Kim ST, Ha SY, Lee S, Ahn S, Lee J, Park SH, et alThe Analysis of Radical Radiotherapy for Locally Advanced
impact of PD-L1 expression in patients with metastatic Cancer of the Uterine Cervix. Br J Radiol 2005;78:821-6.
GEP-NETs. J Cancer 2016;7:484–9. [35] Ishikawa M, Kasamatsu T, Tsuda H, Fukunaga M,
[25] Pei X, Xiang L, Chen W, Jiang W, Yin L, Shen X, et al. Sakamoto A, Kaku T, et al. A Multi-center Retrospective
The Next Generation Sequencing of Cancer-related Genes Study of Neuroendocrine Tumors of the Uterine Cervix:
in Small Cell Neuroendocrine Carcinoma of the Cervix. Prognosis According to the New 2018 Staging System,
Gynecol Oncol 2021;161:779-86. Comparing Outcomes for Different Chemotherapeutic
[26] Hou WH, Schultheiss TE, Wong JY, Wakabayashi MT, Regimens and Histopathological Subtypes. Gynecol Oncol
Chen YJ. Surgery Versus Radiation Treatment for 2019;155:444-51.
High-grade Neuroendocrine Cancer of Uterine Cervix: [36] Wang W, Zhou Y, Wang D, Hu K, Zhang F. Prophylactic
A Surveillance Epidemiology and End Results Database Extended-field Irradiation in Patients with Cervical Cancer:
Analysis. Int J Gynecol Cancer 2018;28:188-93. A Literature Review. Front Oncol 2020;10:579410.
[27] Winer I, Kim C, Gehrig P. Neuroendocrine Tumors of the [37] Zivanovic O, Leitao MM Jr., Park KJ, Zhao H, Diaz JP,
Gynecologic Tract Update. Gynecol Oncol 2021;162:210-9. Konner J, et al. Small Cell Neuroendocrine Carcinoma of
[28] Chen J, Sun Y, Chen L, Zang L, Lin C, Lu Y, et al. the Cervix: Analysis of Outcome, Recurrence Pattern and
Prognostic Factors and Treatment of Neuroendocrine the Impact of Platinum-based Combination Chemotherapy.
Tumors of the Uterine Cervix Based on the FIGO 2018 Gynecol Oncol 2009;112:590-3.
Staging System: A Single-institution Study of 172 Patients. [38] Wang KL, Chang TC, Jung SM, Chen CH, Cheng YM,
PeerJ 2021;9:e11563. Wu HH, et al. Primary Treatment and Prognostic Factors
[29] Ruiz MP, Dziadek OL, Algren SD. Nonsurgical of Small Cell Neuroendocrine Carcinoma of the Uterine
Management of Neuroendocrine Cancer of the Cervix: Cervix: A Taiwanese Gynecologic Oncology Group Study.
Brief Report. Int J Gynecol Cancer 2016;26:1290-2. Eur J Cancer 2012;48:1484-94.

Publisher’s note
AccScience Publishing remains neutral with regard to jurisdictional
claims in published maps and institutional affiliations.
DOI: http://dx.doi.org/10.18053/jctres.09.202304.23-00067